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To the Editor:
We read with great interest the article 
by Um et al.,1 reporting on a prospec-
tive trial in a tertiary referral center to 
compare the diagnostic performance of 
endobronchial ultrasound-guided trans-
bronchial needle aspiration (EBUS-
TBNA) with that of mediastinoscopy 
for nodal staging of patients with 
non–small-cell lung cancer (NSCLC).
Treatment and prognosis in lung 
cancer is critically dependent on stage. In 
the absence of distant metastases, medi-
astinal staging becomes vital for the cor-
rect management of NSCLC. By the way, 
according to recent American College of 
Chest Physicians and European Society 
of Thoracic Surgeons guidelines, mini-
mally invasive endoscopic techniques 
are the first choice if local expertise with 
EBUS/endoscopic ultrasound (EUS) 
needle aspiration is available.2,3
Although mediastinoscopy is con-
sidered the diagnostic standard, several 
meta-analyzes2,4 stated the diagnostic 
sensitivities of EBUS-TBNA range from 
88% to 93%, comparable to those of 
traditional mediastinoscopy (78%) and 
video-assisted mediastinoscopy (89%).
In this setting, the abovementioned 
study strongly supports the diagnostic 
performance of EBUS-TBNA in medias-
tinal staging of cN1–N3 with a sensitiv-
ity and negative predictive value (NPV) 
of 88% and 85.2%, respectively, versus 
81.3% and 78.8% of mediastinoscopy.
Accordingly, we wish to submit 
our reflections to foster brainstorming 
on the strategy for proper work up in 
mediastinal staging of NSCLC.
Recently, Evison et al.5 proposed 
and validated a risk stratification model 
for lymph nodes classified as negative 
by EBUS-TBNA. This model combined 
positron emission  tomography (PET)-
computed tomography and EBUS data 
to stratify patients into high and low risk 
for nodal malignancy. According to the 
authors, this model could aid lung cancer 
multidisciplinary teams in deciding which 
patients need further staging procedures 
after a negative EBUS and which not.
But staging pathway is heavily 
marked by local expertise and profi-
ciency of EBUS operators.
So, while in referral center for 
NSCLC, EBUS-TBNA should be the 
first-choice procedure performed in 
nodal staging and more invasive medi-
astinoscopy should be reserved to fewer 
patients (those with a negative TBNA but 
high suspicion of malignancy according 
to PET-computed tomography/EBUS 
data—high-risk patients in Evison’s 
model—and multidisciplinary team 
decision), in case of less-experienced 
groups the sensitivity of EBUS could 
be lower. Therefore, mediastinoscopy is 
still recommended in this contest.
Are we at the dusk of mediasti-
noscopy in staging of cN1–N3 NSCLC 
in modern clinical practice in experi-
enced center?
Or is mediastinsocopy still a diag-
nostic standard above all in cN0?
By the way, though recent guide-
lines also recommended nodal sampling 
in case of centrally located tumor with 
PET-negative nodes or in case of 5 mm 
nodes, the diagnostic performance of 
EBUS-TBNA is not yet proven in these. 
So mediastinoscopy could be an impor-
tant validation tool of EBUS-TBNA 
results.
On the basis of the data reported, 
we would really appreciate the authors’ 
reflections and reaction on the impact 
of EBUS-TBNA in NSCLC staging and 
the role of mediastinoscopy on modern 
clinical practice.
Dania Nachira, MD
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In Response:
At 2010, the lung cancer team of 
Samsung Medical Center agreed to 
begin the prospective study to directly 
compare the endobronchial ultrasound-
guided transbronchial needle aspiration 
(EBUS-TBNA) with mediastinoscopy 
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in nodal staging of non–small-cell lung 
cancer (NSCLC). We want to evaluate 
the accuracy of EBUS-TBNA and medi-
astinoscopy for nodal staging. The 2-year 
result of 138 consecutive patients was 
that EBUS-TBNA was superior to medi-
astinoscopy. Previous study to compare 
the EBUS-TBNA with mediastinoscopy 
showed no advantage to mediastinos-
copy,1 and later prospective randomized 
trial showed that the accuracy of EBUS 
was similar to mediastinoscopy.2
In addition, meta-analysis of 
11 EBUS-TBNA studies reported the 
sensitivity of 93% and a specificity of 
100%, which are superior to medias-
tinoscopy. There were meta-analysis 
papers for the complication rate, 
showing EBUS-TBNA of 0.05%,3 
compared with mediastinoscopy of 
2%.4 The cost-effectiveness of EBUS-
TBNA was analyzed to be lower 
mean cost and greater mean quality-
adjusted life years compared with 
mediastinoscopy.5
There are increasing train-
ing opportunities for EBUS-TBNA. 
World Association of Bronchology 
and Interventional Pulmonology has 
actively spreading the educational activ-
ities around the world and American 
College of Chest Physicians (ACCP) 
and local Bronchology Societies. 
American Thoracic Society, European 
Respiratory Society, and ACCP recom-
mend that 40 supervised procedures for 
initial training and 20 procedures per 
year to maintain competency. As the 
training activity of EBUS-TBNA are 
increasing, training accessibility will be 
better and better. ACCP and European 
Society of Thoracic Surgeons guide-
lines recommend that EBUS-TBNA 
should be first applied for nodal staging 
of NSCLC.
In conclusion, it is an irresistible 
trend that EBUS-TBNA is the first and 
the best procedure in the nodal staging 
of NSCLC.
Hojoong Kim, MD, PhD
Division of Pulmonary and 
Critical Care Medicine
Department of Medicine, Samsung 
Medical Center
Sungkyunkwan University 
School of Medicine 
Seoul, Korea 
(extrapleural decortication, EP/D) main-
tained that less invasive techniques had to 
be preferred, given the comparable results 
in terms of long-term survival in several 
retrospective cohorts2 and the better early 
postoperative outlook. In the study by 
Bovolato et al3 that we read with interest 
and wish to discuss herein, the decision 
to perform EPP or EP/D was based on a 
careful assessment of the patient’s opera-
tive risk, the tumor staging, and the like-
lihood of completeness of the operation. 
Albeit introducing the clinical staging as 
the tool to drive the surgical indication, 
locally advanced MPM patients were 
treated mainly with EPP; an advantage in 
terms of survival is reported in pathologi-
cal stage IV patients (survival 28 months 
after EPP versus 10.9 months EP/D; 
p, 0.002) but not in earlier stages. One 
can speculate that this advantage is 
because of the fact that a bigger residual 
tumor is left when performing less inva-
sive operation in more advanced stages; 
however, this is an assumption worth of 
further and deeper investigation.
The ongoing dialogue in the sci-
entific community would recommend 
surgery for MPM only in the setting of 
research trials.4 Now, given this level 
of uncertainty, indeed based on the not 
homogeneous data available and the 
mostly retrospective nature of the stud-
ies reported so far, it would seem that the 
role of EPP should be further and care-
fully discussed to substantiate its role in 
“debulking” advanced diseases—more 
efficiently than lesser operations—and/
or treat, with curative intent, early ones.
In the study by Bovolato et al,3 
the best prognosis was detected in those 
patients younger than 70 years, with 
epithelioid MPM, who had received 
chemotherapy, but data failed to show 
a statistically significant advantage of 
surgical treatment overall versus non-
surgical one. Surprisingly, no statisti-
cally significant interaction was detected 
between the type of treatment and the 
clinical stages in terms of overall sur-
vival; anyway, Table 1 of Bovolato et al3 
shows that 51% and 38.9% of patients 
undergoing, respectively, EP/D and EPP 
had an unknown clinical stage, there-
fore setting a situation in which, likely, 
the extent of the surgical approach was 
decided intraoperatively. Correctly, 
the authors state the limits of clinical 
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To the Editor:
The role of surgery in the manage-
ment of malignant pleural mesothelioma 
(MPM) is a forum of alive and kicking 
discussion: survival advantages stay 
substantially unproven. To the best of 
our knowledge, the Mesothelioma and 
Radical Surgery (MARS) study, so far the 
only prospective randomized trial whose 
results have been published in the English 
literature,1 concluded a negative outcome 
of extrapleural pneumonectomy (EPP) in 
a limited case series. On these evidences, 
advocates for lung-sparing approaches 
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